<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562818</url>
  </required_header>
  <id_info>
    <org_study_id>INCancerologiaMexico</org_study_id>
    <nct_id>NCT04562818</nct_id>
  </id_info>
  <brief_title>Results From a Mexican Acute Promyelocytic Leukemia.</brief_title>
  <acronym>Mexico APL</acronym>
  <official_title>Results From a Mexican Long-term Multicentric Study on Acute Promyelocytic Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancerologia de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective, observational study, comparing treatments of acute promyelocytic leukemia in&#xD;
      different centers in México.&#xD;
&#xD;
      There is no sufficient information about acute promyelocytic leukemia in America Latina,&#xD;
      particularly in Mexico.&#xD;
&#xD;
      For these reason the investigators started a study adding all promyelocityc patients from the&#xD;
      main Hospital in Mexico in order to put together a group of patient and analyze the response,&#xD;
      overall survival and what are the characteristics of the population.&#xD;
&#xD;
      The investigators included 5 Hospital in Mexico City and states as Monterrey, Guadalajara,&#xD;
      San Luis Potosi, Puebla, Veracruz, Yucatán, Oaxaca, Guanajuato, Estado de México.&#xD;
&#xD;
      Even do, the investigators didn´t have arsenic trioxide they are treating patients with&#xD;
      standard chemotherapy. These paper will help to show the authorities that the cost of&#xD;
      treating patient with standard chemotherapy is much more higher than ATO-ATRA. The&#xD;
      investigators are now doing a cost benefit analysis so the investigators, can soon have ATO&#xD;
      treatment as standard of care in Mexico for the treatment of acute promyelocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicentric, retrospective, descriptive, longitudinal study was carried out. Between&#xD;
      January 2007 and January 2017, patients of both sexes and different ages, who were candidates&#xD;
      for receiving intensive chemotherapy along with tretinoin were included in the study. The&#xD;
      diagnosis for Acute Promyelocytic Leukemia was determined based on the following criteria:&#xD;
      abnormal promyelocytes in the bone marrow and verification of the t(15;17) translocation by&#xD;
      karyotype or using RT-PCR to determine the genetic lesion and define the type of PML/RARA&#xD;
      isoform.&#xD;
&#xD;
      In Mexico the investigators still treating patients with anthracycline and cytarabine +&#xD;
      transretinoic acid. These information will help the authorities to realize the importance of&#xD;
      having arsenic trioxide as part of the treatment of these disease, knowing the amount of&#xD;
      patient that the investigators have in Mexico, knowing that in the hispanic race the&#xD;
      incidence is greater.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2007</start_date>
  <completion_date type="Actual">January 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival in Mexico in patients with acute promyelocytic leukemia</measure>
    <time_frame>January 2007- January 2017</time_frame>
    <description>Overall survival in different institutions in Mexico, in patient with diagnostic with acute promyelocytic leukemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in survival with different anthracycline (Daunorrubicin vs idarrubicin)</measure>
    <time_frame>January 2007-January 2017</time_frame>
    <description>Event free survival and overall survival with different anthracyclin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications with different anthracycline</measure>
    <time_frame>January 2007-January 2017</time_frame>
    <description>Complications</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">360</enrollment>
  <condition>Promyelocytic Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>Daunorrubicin</arm_group_label>
    <description>Patient treated with daunorrubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idarrubicin</arm_group_label>
    <description>Patient treated with idarrubicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnosis</intervention_name>
    <description>Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)</description>
    <arm_group_label>Daunorrubicin</arm_group_label>
    <arm_group_label>Idarrubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Molecular and Karyotype</intervention_name>
    <description>To realize the need of having more center we the technology to perform all of these tests</description>
    <arm_group_label>Daunorrubicin</arm_group_label>
    <arm_group_label>Idarrubicin</arm_group_label>
    <other_name>FISH</other_name>
    <other_name>Karyotype</other_name>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Leucocytes</intervention_name>
    <arm_group_label>Daunorrubicin</arm_group_label>
    <arm_group_label>Idarrubicin</arm_group_label>
    <other_name>Risk status</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patient older 15 years old with acute promyelocytic Leukemia treated at a Mecican&#xD;
        Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Actute Promyelocytic leukemia PML/RAR alfa + Diabetes mellitus Hypertension Asthma&#xD;
             Chronic renal disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non Acute Promyelocytic leukemia Younger than 15 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nidia Zapata</name>
      <address>
        <city>Mexico</city>
        <state>Mexico City</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25. Review.</citation>
    <PMID>30803991</PMID>
  </results_reference>
  <results_reference>
    <citation>Cicconi L, Fenaux P, Kantarjian H, Tallman M, Sanz MA, Lo-Coco F. Molecular remission as a therapeutic objective in acute promyelocytic leukemia. Leukemia. 2018 Aug;32(8):1671-1678. doi: 10.1038/s41375-018-0219-5. Epub 2018 Jul 19. Review.</citation>
    <PMID>30026570</PMID>
  </results_reference>
  <results_reference>
    <citation>Ryan MM. Acute Promyelocytic Leukemia: A Summary. J Adv Pract Oncol. 2018 Mar;9(2):178-187. Epub 2018 Mar 1. Review.</citation>
    <PMID>30588352</PMID>
  </results_reference>
  <results_reference>
    <citation>Warrell RP Jr, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993 Jul 15;329(3):177-89. Review.</citation>
    <PMID>8515790</PMID>
  </results_reference>
  <results_reference>
    <citation>Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 1998 May 1;91(9):3093-102. Review.</citation>
    <PMID>9558362</PMID>
  </results_reference>
  <results_reference>
    <citation>Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood. 1992 Feb 1;79(3):543-53. Review.</citation>
    <PMID>1732003</PMID>
  </results_reference>
  <results_reference>
    <citation>Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993 Dec 1;82(11):3241-9.</citation>
    <PMID>8241496</PMID>
  </results_reference>
  <results_reference>
    <citation>Krutova TV, Linchina LP, Korman DB, Isaev NM, Shkrob OS. [Autoradiographic study of the gastric mucosa in cancer]. Vopr Onkol. 1976;22(10):8-13. Russian.</citation>
    <PMID>189506</PMID>
  </results_reference>
  <results_reference>
    <citation>Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH Jr, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995 Feb 15;85(4):1083-94.</citation>
    <PMID>7849296</PMID>
  </results_reference>
  <results_reference>
    <citation>Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. Blood. 2016 Jul 21;128(3):462-463. doi: 10.1182/blood-2016-06-721662.</citation>
    <PMID>31659364</PMID>
  </results_reference>
  <results_reference>
    <citation>Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. doi: 10.1182/blood-2010-08-302950. Epub 2011 Mar 8.</citation>
    <PMID>21385856</PMID>
  </results_reference>
  <results_reference>
    <citation>Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. doi: 10.1182/blood-2010-02-269621. Epub 2010 Aug 12.</citation>
    <PMID>20705755</PMID>
  </results_reference>
  <results_reference>
    <citation>Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.</citation>
    <PMID>27400939</PMID>
  </results_reference>
  <results_reference>
    <citation>Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J, Powles RL, Catovsky D. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol. 1997 Feb;96(2):314-21.</citation>
    <PMID>9029019</PMID>
  </results_reference>
  <results_reference>
    <citation>Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. Epub 2012 Jun 19.</citation>
    <PMID>22715121</PMID>
  </results_reference>
  <results_reference>
    <citation>Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998 Oct 1;92(7):2322-33.</citation>
    <PMID>9746770</PMID>
  </results_reference>
  <results_reference>
    <citation>De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, Bordessoule D, San Miguel J, Link H, Desablens B, Stamatoullas A, Deconinck E, Geiser K, Hess U, Maloisel F, Castaigne S, Preudhomme C, Chomienne C, Degos L, Fenaux P; European APL Group. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000 Dec;111(3):801-6.</citation>
    <PMID>11122141</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancerologia de Mexico</investigator_affiliation>
    <investigator_full_name>Nidia Paulina Zapata-Canto</investigator_full_name>
    <investigator_title>Assistant Professor of Hematology Department (Acute Myeloid Leukemia)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Plan is to published the information in Mexico, so we can start planing with the Mexican government the cost of treating a patient with Chemotherapy vs ATO/ATRA</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

